 |
市場調査レポート
商品コード
1345330
帯状疱疹ワクチンの世界市場 (2023-2030年)：製品タイプ (Shingrix・Zostavax)・ワクチンタイプ (組換えワクチン・弱毒化ワクチン) 別の規模・シェア・成長分析・予測Global Shingles Vaccine Market Size, Share, Growth Analysis, By Product(Shingrix, Zostavax), By Vaccine Type(Recombinant Vaccine, and Live Attenuated Vaccine) - Industry Forecast 2023-2030 |
||||||
| 帯状疱疹ワクチンの世界市場 (2023-2030年)：製品タイプ (Shingrix・Zostavax)・ワクチンタイプ (組換えワクチン・弱毒化ワクチン) 別の規模・シェア・成長分析・予測 |
|
出版日: 2023年08月12日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の帯状疱疹ワクチンの市場規模は、2021年の35億米ドル、2022年の39億9,000万米ドルから、予測期間中は7.6%のCAGRで推移し、2030年には112億9,000万米ドルの規模に成長すると予測されています。
世界の帯状疱疹ワクチンの市場は、人口の高齢化、帯状疱疹と関連の合併症の予防におけるワクチンの有効性に関する認知度の向上、さまざまな地域におけるワクチン接種プログラムの拡大など、複合的な要因によって、今後数年間の渡って力強い成長が見込まれています。同市場では、弱毒生ワクチンと遺伝子組換えサブユニットワクチンの両方の需要が着実に増加しており、後者はその安全性プロファイルから支持を集めています。さらに、ワクチンの有効性とアクセシビリティの向上に向けたR&Dが進められており、成人へのワクチン接種を促進する政府の取り組みも相まって、市場拡大に拍車がかかると予想されています。製薬業界の主要企業は、この拡大する市場機会を活用するため、技術革新と戦略的提携に注力すると予想されています。
世界の帯状疱疹ワクチン市場の主要動向の一つは、高齢化社会における予防ヘルスケアと予防接種プログラムへの注力の拡大です。政府および医療機関は、帯状疱疹ワクチン接種キャンペーンを積極的に推進しており、ワクチン接種率の上昇につながっています。さらに、より効果的で長持ちするワクチンの開発など、ワクチン技術の進歩も市場成長をさらに促進させると考えられています。
当レポートでは、世界の帯状疱疹ワクチンの市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。
目次
- エグゼクティブサマリー
- 調査手法
- 親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 主要市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要成功要因
- 競合の程度
- 市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 市場力学
- 規制状況
- ポーターの分析
- 将来のディスラプションに関するSkyquestの特別な洞察
- 世界の帯状疱疹ワクチン市場：製品別
- 市場概要
- Shingrix
- Zostavax
- SKYZoster
- 世界の帯状疱疹ワクチン市場：ワクチンタイプ別
- 市場概要
- 組換えワクチン
- 弱毒化生ワクチン
- 世界の帯状疱疹ワクチン市場：地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
- 競合情勢
- トップ5社の比較
- 主要企業の市場での位置付け
- 主要企業の採用戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア
- 主要企業プロファイル
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- SK chemicals
- Green Cross Corp
- Geneone Life Science
- Vaccitech
- CanSinoBIO
Global Shingles Vaccine Market size was valued at USD 3.5 Billion in 2021 and is poised to grow from USD 3.99 Billion in 2022 to USD 11.29 Billion by 2030, growing at a CAGR of 7.6% in the forecast period (2023-2030).
The Global Shingles Vaccine Market is poised for robust growth in the coming years, driven by a combination of factors including an aging population, increasing awareness about the vaccine's effectiveness in preventing shingles and related complications, and expanding vaccination programs in various regions. The market is witnessing a steady rise in demand for both live attenuated and recombinant subunit shingles vaccines, with the latter gaining traction due to its safety profile. Furthermore, ongoing research and development efforts to improve vaccine efficacy and accessibility, coupled with government initiatives to promote adult vaccination, are anticipated to fuel market expansion. Key players in the pharmaceutical industry are expected to focus on innovation and strategic collaborations to capitalize on this growing market opportunity.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Shingles Vaccine Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report:
The shingles vaccine market is segmented based on Product, Vaccine Type, and Regional. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future. Based on Product the market is segmented as, Shingrix, Zostavax, SKYZoster. Based on Vaccine Type the market is segmented as, Recombinant Vaccine, Live Attenuated Vaccine. Based on Regional the market is segmented as, North America, Asia Pacific, Latin America, Middle East & Africa (MEA).
Driver:
The Global Shingles Vaccine Market is experiencing significant growth driven by several key factors. Firstly, an aging population worldwide has led to a higher susceptibility to shingles, creating a robust demand for preventive vaccines. Additionally, rising awareness about the importance of vaccination and the efficacy of shingles vaccines in reducing the severity and incidence of the disease is fueling market expansion. Furthermore, government initiatives and healthcare policies aimed at promoting adult immunization are bolstering market adoption. The introduction of innovative vaccines, such as recombinant subunit vaccines, is also contributing to market growth by offering improved efficacy and reduced side effects. Overall, the Global Shingles Vaccine Market is poised for continued expansion as the global healthcare community prioritizes prevention and immunization against shingles.
Restraint:
The Global Shingles Vaccine Market is currently experiencing several restraints that are impacting its growth trajectory. Firstly, the high cost of shingles vaccines has limited accessibility for a significant portion of the population, particularly in low- and middle-income countries, thus impeding market expansion. Secondly, the limited awareness about the severity of shingles and the benefits of vaccination among the general public is hindering the market's potential. Additionally, logistical challenges in vaccine distribution and storage, especially in remote areas, pose a significant barrier to market penetration. Lastly, regulatory hurdles and the lack of reimbursement policies in some regions are inhibiting market growth, making it crucial for stakeholders to address these constraints to unlock the full potential of the global shingles vaccine market.
Market Trends:
One key market trend in the Global Shingles Vaccine Market is the growing emphasis on preventive healthcare and immunization programs among aging populations. As the world's elderly population continues to expand, there is an increasing awareness of the importance of shingles vaccination in reducing the risk of this painful and debilitating condition. Governments and healthcare organizations are actively promoting shingles vaccination campaigns, leading to rising vaccine adoption rates. Additionally, advancements in vaccine technology, such as the development of more effective and longer-lasting vaccines, are anticipated to further drive market growth. Overall, the Global Shingles Vaccine Market is poised for significant expansion as a result of these demographic and technological factors.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Shingles Vaccine Market by Product
- Market Overview
- Shingrix
- Zostavax
- and SKYZoster
- Global Shingles Vaccine Market by Vaccine Type
- Market Overview
- Recombinant Vaccine
- and Live Attenuated Vaccine
- Global Shingles Vaccine Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- GlaxoSmithKline plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SK chemicals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Green Cross Corp
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Geneone Life Science
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vaccitech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CanSinoBIO
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
